SCHEMBL885170

SCHEMBL885170

c1cncc(C(Cc2cccnc2-c2ccncc2)c2cccnc2)c1

nearest known ligand 0.68

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 17/20 0.68
KCNH2 Q12809 7/20 0.68
CFTR P13569 1/20 0.41
SLC6A2 P23975 1/20 0.41
SLC6A4 P31645 1/20 0.41
SLC6A3 Q01959 1/20 0.41
GOPC Q9HD26 1/20 0.41
KCNN4 O15554 1/20 0.40
TSHR P16473 2/20 0.40
MAPK1 P28482 1/20 0.40
LMNA P02545 1/20 0.40
NR2F2 P24468 1/20 0.40
STAT3 P40763 1/20 0.40
HTT P42858 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL884728 0.93 KCNA5 (0.74) KCNA5KCNH2CFTRSLC6A2SLC6A4
SCHEMBL885826 0.90 KCNA5 (0.74) KCNA5KCNH2KCNN4TSHRMAPK1
SCHEMBL884939 0.87 KCNA5 (0.64) KCNA5KCNH2
SCHEMBL884536 0.87 KCNA5 (0.75) KCNA5KCNH2
SCHEMBL884508 0.87 KCNA5 (0.64) KCNA5KCNH2SMN1; SMN2
SCHEMBL884767 0.87 KCNA5 (0.77) KCNA5KCNH2
SCHEMBL885908 0.84 KCNA5 (0.60) KCNA5KCNH2
SCHEMBL884613 0.84 KCNA5 (0.63) KCNA5KCNH2
SCHEMBL885103 0.84 KCNA5 (0.60) KCNA5KCNH2
SCHEMBL884653 0.83 KCNA5 (0.81) KCNA5KCNH2KCNN4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233897-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2009-09-17 US claimed
EP-1940406-A2 POTASSIUM CHANNEL INHIBITORS Merck and Co., Inc. (US) 2008-07-09 EP claimed
WO-2007050348-A2 POTASSIUM CHANNEL INHIBITORS MERCK & CO., INC. (US) 2007-05-03 WO claimed
US-8148535-B2 Potassium channel inhibitors MERCK SHARP & DOHME CORP. (US) 2012-04-03 US disclosed
US-20090233897-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2009-09-17 US disclosed
EP-1940406-A2 POTASSIUM CHANNEL INHIBITORS Merck and Co., Inc. (US) 2008-07-09 EP disclosed
WO-2007050348-A2 POTASSIUM CHANNEL INHIBITORS MERCK & CO., INC. (US) 2007-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233897-A1 Potassium Channel Inhibitors KCNJ2, KCNQ2, KCNH2 KCNA5 11/4885KCNH2 3/4885CFTR 256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.